Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors

Get up to date on the use of newly approved and emerging PARP inhibitors for the treatment of patients with metastatic CRPC and DNA repair defects. Includes a case study!
Celestia Higano Headshot
Celestia S. Higano, MD, FACP
Charles J. Ryan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 744 KB
Released: July 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Video discussion by Drs. Wassim Abida, Heather Cheng, and Maha Hussain on optimal use of PARP inhibitors in prostate cancer, from Clinical Care Options (CCO)

Maha Hussain, MD, FACP, FASCO
Program Director
person default Wassim Abida, MD, PhD Heather H. Cheng, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: March 30, 2022 Expired: March 29, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings